In a regulatory filing, Glenmark said, “…due to medical necessity and potential drug shortage expectations, the USFDA has provided an exception, which enables the Company to supply Atovaquone Oral Suspension USP 750mg/5ml to the US market”.
Copyright © 2024 | WordPress Theme by MH Themes